Pfizer Says Phase 3 OPAL Studies For Xeljanz Met Primary Efficacy Endpoints

Pfizer Inc. (PFE) said that new results from the Phase 3 Oral Psoriatic Arthritis TriaL (OPAL) studies, Broaden and Beyond, will be presented at the 2016 ACR/ARHP Annual Meeting from November 11 to 16 in Washington, DC.

from RTT - Biotech http://ift.tt/2fQV6TK
via IFTTT